• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA approves Sandoz's third biosimilar

Publication
Article
Dermatology TimesDermatology Times, January 2019 (Vol. 40, No. 1)
Volume 40
Issue 1

Sandoz, a division of Novartis, announced that the U.S. Food and Drug Administration approved its biosimilar, adalimumabadaz (Hyrimoz, Novartis AG). 

psoriatic arthritis

Sandoz, a division of Novartis, announced that the U.S. Food and Drug Administration approved its biosimilar, adalimumabadaz (Hyrimoz, Novartis AG). (©AdamJ/Shutterstock.com)

On Oct. 31, Sandoz, a division of Novartis, announced that the U.S. Food and Drug Administration approved its biosimilar, adalimumabadaz (Hyrimoz, Novartis AG), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis in patients four years of age and older, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.

In clinical trials, adalimumab-adaz was shown to match the safety, efficacy and quality of its reference biologic. Adalimumab-adaz met its primary endpoint in a randomized, double-blind, three-arm, parallel study confirming its pharmacokinetics, immunogenicity and safety. A follow-up study demonstrated therapeutic equivalence in patients with moderate to severe chronic plaque-type psoriasis.

Adalimumab-adaz is the third FDA-approved biosimilar for Sandoz in the U.S.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.